StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Instinet Starts Sarepta Therapeutics (SRPT) at Buy, $84 PT
March 1, 2017 4:24 PM
Instinet initiates coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Buy rating and a price target of $84.00.Analyst Christopher Marai ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot New Coverage
New Coverage
Next Articles
Sarepta Therapeutics (SRPT) Sees Strong Red-to-Green Reversal
March 1, 2017 11:17 AM
Oppenheimer Maintains Outperform Rating and $76 PT on Sarepta Therapeutics (SRPT) Following In-line FY17 Sales Guidance Estimates
March 1, 2017 9:38 AM
Pre-Open Stock Movers 03/01: (CLNE) (DVAX) (LOW) Higher; (PANW) (ENPH) (SRPT) Lower (more...)
March 1, 2017 9:24 AM
Sarepta Therapeutics (SRPT) PT Lowered to $75 at Needham & Company; 'FY17 Guidance Significantly Below Expectations'
March 1, 2017 7:44 AM
Sarepta Therapeutics (SRPT) PT Lowered to $27 at Leerink Partners
March 1, 2017 7:34 AM
UPDATE: Sarepta Therapeutics (SRPT) PT Lowered to $27 at Jefferies
March 1, 2017 7:29 AM
Sarepta Therapeutics (SRPT) PT Lowered to $48 at JMP Securities
March 1, 2017 7:11 AM
Baird Reiterates Outperform Rating and $102 PT on Sarepta Therapeutics (SRPT); Mgmt Upbeat on Exondys 51 Launch
March 1, 2017 6:52 AM
Sarepta Therapeutics (SRPT) PT Lowered to $91 at RBC Capital
March 1, 2017 6:35 AM
